Insulin levels, insulin resistance and the use of metformin in polycystic ovary syndrome [2]

Medical Journal of Australia

Volumn 186, Issue 5, 2007, Pages 268-269

  Hutchison, Samantha K ^a   Zoungas, Sophia ^b   Teede, Helena J ^a,b  

^a Jean Hailes Foundation for Women's Health   (Australia)

^b Diabetes Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN SENSITIZING AGENT; METFORMIN;

ANOVULATION; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; DIET RESTRICTION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INFERTILITY THERAPY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LETTER; LIFESTYLE MODIFICATION; MULTIPLE PREGNANCY; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE;

EID: 33947208059     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb00889.x     Document Type: Letter

References (6)

1. Samaras K, McElduff A, Twigg SM, et al. Insulin levels in insulin resistance: phantom of the metabolic opera? Med J Aust 2006; 185: 159-161.
2. Teede HJ, Hutchison SK, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 2006; 30: 45-53.
3. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-1474.
4. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; (3): CD003053.
5. Teede HJ, Meyer C, Norman RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 2005; 6: 2419-2427.
6. Palomba S, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4068-4074.